BACKGROUND:HIV-infected children are at heightened risk for severe influenza illness; however, there is no study on the efficacy or effectiveness of influenza vaccine in these children. We evaluated the safety, immunogenicity, and efficacy of nonadjuvanted, trivalent inactivated influenza vaccine (TIV) against confirmed seasonal influenza virus illness in HIV-infected children. METHODS: A double-blind, placebo-controlled trial was undertaken in Johannesburg in 2009. Four hundred and ten children were randomized to two doses of TIV or placebo 1 month apart. Nasopharyngeal aspirates obtained at respiratory illness visits were tested by influenza-specific reverse transcriptase-PCR (RT-PCR). Vaccine immunogenicity was evaluated by hemagglutinin inhibition (HAI) assay. Influenza isolates were sequenced and evaluated in maximum likelihood phylogenetic analysis. RESULTS: Overall, the median age of participants was 23.8 months and their median CD4% was 33.5. Ninety-two percent of enrolees were on antiretroviral therapy. Among children receiving both doses of vaccine/placebo, confirmed seasonal influenza illness occurred in 13 (all H3N2) of 205 TIV recipients and 17 (15 H3N2 and two influenza B) of 200 placebo recipients with vaccine efficacy of 17.7% (95% confidence interval <0-62.4%). The proportion of TIV recipients who seroconverted after second dose against vaccine strains of H1N1, H3N2, and influenza B were 47.5, 50.0, and 40.0%, compared to 4.7, 11.6, and 0%, respectively among placebo recipients. There were no TIV-related serious adverse events. Sequence analysis of wild-type H3N2 strains indicated drift from the H3N2 vaccine strain. CONCLUSION: Poor immunogenicity of TIV, coupled with drift of circulating H3N2 wild-type compared to vaccine strain, may explain the lack of efficacy of TIV in young HIV-infected children. Alternate TIV vaccine schedules or formulations warrant evaluation for efficacy in HIV-infected children.
RCT Entities:
BACKGROUND:HIV-infectedchildren are at heightened risk for severe influenza illness; however, there is no study on the efficacy or effectiveness of influenza vaccine in these children. We evaluated the safety, immunogenicity, and efficacy of nonadjuvanted, trivalent inactivated influenza vaccine (TIV) against confirmed seasonal influenza virus illness in HIV-infectedchildren. METHODS: A double-blind, placebo-controlled trial was undertaken in Johannesburg in 2009. Four hundred and ten children were randomized to two doses of TIV or placebo 1 month apart. Nasopharyngeal aspirates obtained at respiratory illness visits were tested by influenza-specific reverse transcriptase-PCR (RT-PCR). Vaccine immunogenicity was evaluated by hemagglutinin inhibition (HAI) assay. Influenza isolates were sequenced and evaluated in maximum likelihood phylogenetic analysis. RESULTS: Overall, the median age of participants was 23.8 months and their median CD4% was 33.5. Ninety-two percent of enrolees were on antiretroviral therapy. Among children receiving both doses of vaccine/placebo, confirmed seasonal influenza illness occurred in 13 (all H3N2) of 205 TIV recipients and 17 (15 H3N2 and two influenza B) of 200 placebo recipients with vaccine efficacy of 17.7% (95% confidence interval <0-62.4%). The proportion of TIV recipients who seroconverted after second dose against vaccine strains of H1N1, H3N2, and influenza B were 47.5, 50.0, and 40.0%, compared to 4.7, 11.6, and 0%, respectively among placebo recipients. There were no TIV-related serious adverse events. Sequence analysis of wild-type H3N2 strains indicated drift from the H3N2 vaccine strain. CONCLUSION: Poor immunogenicity of TIV, coupled with drift of circulating H3N2 wild-type compared to vaccine strain, may explain the lack of efficacy of TIV in young HIV-infectedchildren. Alternate TIV vaccine schedules or formulations warrant evaluation for efficacy in HIV-infectedchildren.
Authors: Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser Journal: Neuro Oncol Date: 2014-04-08 Impact factor: 12.300
Authors: Aldiouma Diallo; Ousmane M Diop; Doudou Diop; Mbayame Nd Niang; Jonathan D Sugimoto; Justin R Ortiz; El Hadji Abdourahmane Faye; Bou Diarra; Deborah Goudiaby; Kristen D C Lewis; Shannon L Emery; Sahar Z Zangeneh; Kathryn E Lafond; Cheikh Sokhna; M Elizabeth Halloran; Marc-Alain Widdowson; Kathleen M Neuzil; John C Victor Journal: Clin Infect Dis Date: 2019-10-30 Impact factor: 9.079
Authors: Karen K Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J Ward; Curtis Cooper Journal: J Clin Immunol Date: 2014-05-14 Impact factor: 8.317
Authors: Ingrid Peterson; Naor Bar-Zeev; Neil Kennedy; Antonia Ho; Laura Newberry; Miguel A SanJoaquin; Mavis Menyere; Maaike Alaerts; Gugulethu Mapurisa; Moses Chilombe; Ivan Mambule; David G Lalloo; Suzanne T Anderson; Thembi Katangwe; Nigel Cunliffe; Nico Nagelkerke; Meredith McMorrow; Marc-Allain Widdowson; Neil French; Dean Everett; Robert S Heyderman Journal: J Infect Dis Date: 2016-09-13 Impact factor: 5.226
Authors: Adriana Weinberg; Donna Curtis; Mariangeli Freitas Ning; David Jeremy Claypool; Emilie Jalbert; Julie Patterson; Daniel N Frank; Diana Ir; Carl Armon Journal: Front Immunol Date: 2016-04-15 Impact factor: 7.561
Authors: Melissa A Rolfes; Doli Goswami; Amina Tahia Sharmeen; Sultana Yeasmin; Nasrin Parvin; Kamrun Nahar; Mustafizur Rahman; Marion Barends; Dilruba Ahmed; Mohammed Ziaur Rahman; Joseph Bresee; Stephen Luby; Lawrence H Moulton; Mathuram Santosham; Alicia M Fry; W Abdullah Brooks Journal: Vaccine Date: 2017-10-31 Impact factor: 3.641